Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Kuninobu Kanai"'
Autor:
Miwako Kogure, Eri Takase, Aya Fusamoto, Koichi Sato, Yukiko Tsuchihashi, Hirotaka Nakanishi, Takeshi Ikeda, Tomokazu Kuchibiro, Yoshimitsu Hirai, Kuninobu Kanai
Publikováno v:
Respirology Case Reports, Vol 11, Iss 3, Pp n/a-n/a (2023)
Abstract Pulmonary nocardiosis is a rare disease that is often difficult to cure because of its tendency to recur. Here, we report a case of refractory localized pulmonary nocardiosis caused by Nocardia mexicana. A 60‐year‐old Japanese woman had
Externí odkaz:
https://doaj.org/article/3521067e35244215961756ab5fb5c30c
Autor:
Mio Ikeda, Yasuhiro Koh, Shunsuke Teraoka, Koichi Sato, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Hiroaki Akamatsu, Yuichi Ozawa, Keiichiro Akamatsu, Katsuya Endo, Masayuki Higuchi, Masanori Nakanishi, Hiroki Ueda, Nobuyuki Yamamoto
Publikováno v:
Cancer Medicine, Vol 9, Iss 6, Pp 2122-2133 (2020)
Abstract Noninvasive diagnostics using circulating tumor cells (CTCs) are expected to be useful for decision making in precision cancer therapy. AXL, a receptor tyrosine kinase is associated with tumor progression, epithelial‐to‐mesenchymal trans
Externí odkaz:
https://doaj.org/article/93df0d4a0bea451c9197d68d6d5d0747
Autor:
Nobukazu Fujimoto, MD, PhD, Morihito Okada, MD, PhD, Takashi Kijima, MD, PhD, Keisuke Aoe, MD, PhD, Terufumi Kato, MD, Kazuhiko Nakagawa, MD, PhD, Yuichiro Takeda, MD, PhD, Toyoaki Hida, MD, PhD, Kuninobu Kanai, MD, PhD, Jun Hirano, MPharm, Yuichiro Ohe, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100135- (2021)
Introduction: We examined the long-term efficacy and safety of nivolumab, a human monoclonal antibody that inhibits interactions between the programmed cell death protein-1 receptor and its ligands (programmed death-ligand 1 and programmed death-liga
Externí odkaz:
https://doaj.org/article/6daaa024a9364fefa2c9b2eb6842a85c
Autor:
Nobuyuki Yamamoto, Yuichi Ozawa, Takeya Sugimoto, Yuichiro Azuma, Yuhei Harutani, Takanori Yoshikawa, Kuninobu Kanai
Publikováno v:
BMJ Open, Vol 10, Iss 7 (2020)
Introduction Triplet regimen of carboplatin or cisplatin with pemetrexed and pembrolizumab is a standard treatment for patients with advanced, chemo-naïve, non-squamous non-small cell lung cancer. However, subgroup analysis for patients aged ≥75 y
Externí odkaz:
https://doaj.org/article/9c2038878ed14ed7b537c26e00ac1389
Autor:
Satomi Yagi, Yasuhiro Koh, Hiroaki Akamatsu, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Keiichiro Akamatsu, Katsuya Endo, Seita Nakamura, Masayuki Higuchi, Hisashige Kanbara, Masanori Nakanishi, Hiroki Ueda, Nobuyuki Yamamoto
Publikováno v:
PLoS ONE, Vol 12, Iss 6, p e0179744 (2017)
Circulating tumor cells (CTCs), defined as tumor cells circulating in the peripheral blood of patients with solid tumors, are relatively rare. Diagnosis using CTCs is expected to help in the decision-making for precision cancer medicine. We have deve
Externí odkaz:
https://doaj.org/article/9cf28ee5e7b1459cbef8ed0437b545d4
Autor:
Yuichiro Ohe, Yoshinobu Namba, Jun Hirano, Hiroshi Tanaka, Mitsuhiro Takenoyama, Toshiaki Takahashi, Satoshi Oizumi, Fumio Imamura, Kuninobu Kanai, Toyoaki Hida, Yuichiro Takeda, Kazuhiko Nakagawa, Nobukazu Fujimoto, Terufumi Kato, Keisuke Aoe, Takashi Kijima, Morihito Okada
Criteria for discontinuation of nivolumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29ecdfef4a2438b96568eeb37ae73449
https://doi.org/10.1158/1078-0432.22471298.v1
https://doi.org/10.1158/1078-0432.22471298.v1
Autor:
Yuichiro Ohe, Yoshinobu Namba, Jun Hirano, Hiroshi Tanaka, Mitsuhiro Takenoyama, Toshiaki Takahashi, Satoshi Oizumi, Fumio Imamura, Kuninobu Kanai, Toyoaki Hida, Yuichiro Takeda, Kazuhiko Nakagawa, Nobukazu Fujimoto, Terufumi Kato, Keisuke Aoe, Takashi Kijima, Morihito Okada
Kaplan-Meier curves for overall survival (A) and progressionfree survival (B) for all patients according tumor type (epithelioid and non-epithelioid subtypes)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5118aba423ec04cf8abe0e7dc030672c
https://doi.org/10.1158/1078-0432.22471304
https://doi.org/10.1158/1078-0432.22471304
Autor:
Eri Takase, Hiroaki Akamatsu, Shunsuke Teraoka, Keita Nakaguchi, Masanori Tanaka, Takahiro Kaki, Katsuyuki Furuta, Koichi Sato, Eriko Murakami, Takeya Sugimoto, Ryota Shibaki, Daichi Fujimoto, Atsushi Hayata, Nahomi Tokudome, Yuichi Ozawa, Yasuhiro Koh, Masanori Nakanishi, Kuninobu Kanai, Toshio Shimokawa, Nobuyuki Yamamoto
Background: The efficacy and tolerability of high-flow nasal cannula (HFNC) for relieving dyspnea in advanced cancer patients with limited prognosis requires elucidation. Methods: Patients with advanced cancer who had dyspnea at rest (numeric rating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::053072e04eee67e8700506ed3cf47b14
https://doi.org/10.21203/rs.3.rs-2639256/v1
https://doi.org/10.21203/rs.3.rs-2639256/v1
Autor:
Nahomi Tokudome, Katsuya Endo, Hiroaki Akamatsu, Atsushi Hayata, Keiichiro Akamatsu, Hiroki Ueda, Mio Ikeda, Nobuyuki Yamamoto, Shunsuke Teraoka, Koichi Sato, Masanori Nakanishi, Masayuki Higuchi, Yasuhiro Koh, Kuninobu Kanai, Yuichi Ozawa
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 6, Pp 2122-2133 (2020)
Cancer Medicine, Vol 9, Iss 6, Pp 2122-2133 (2020)
Noninvasive diagnostics using circulating tumor cells (CTCs) are expected to be useful for decision making in precision cancer therapy. AXL, a receptor tyrosine kinase is associated with tumor progression, epithelial‐to‐mesenchymal transition (EM
Autor:
Takashi Kijima, Hiroshi Tanaka, Kazuhiko Nakagawa, Keisuke Aoe, Mitsuhiro Takenoyama, Morihito Okada, Toshiaki Takahashi, Yuichiro Ohe, Yuichiro Takeda, Toyoaki Hida, Terufumi Kato, Yoshinobu Namba, Fumio Imamura, Satoshi Oizumi, Jun Hirano, Kuninobu Kanai, Nobukazu Fujimoto
Publikováno v:
Clinical Cancer Research. 25:5485-5492
Purpose: Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with poor prognosis. Patients with MPM who do not respond to standard first-line chemotherapy have limited treatment options. We evaluated the efficacy and safety of ni